India Neurodegeneration Epidemiology

India Neurodegeneration Epidemiology

Overview

India presents a unique epidemiological challenge:

• World's most populous nation (1.4+ billion)
• Rapid demographic transition: aging population growing rapidly
• Significant regional variation in demographics and healthcare access
• Historically underrecognized neurodegenerative diseases
• Emerging research infrastructure but limited data

Alzheimer's Disease

Prevalence (2024-2025)

| Age Group | Prevalence Rate | Estimated Number |
|-----------|-----------------|------------------|
| 60-64 years | ~2-3% | ~3-4 million |
| 65-69 years | ~3-4% | ~4-5 million |
| 70-74 years | ~6-8% | ~5-6 million |
| 75-79 years | ~10-12% | ~4-5 million |
| 80+ years | ~15-20% | ~3-4 million |
| Total (60+) | ~5-7% | ~8-10 million |
| Total (all ages) | ~0.6-0.8% | ~8-10 million |

Key Characteristics:

• Lower reported prevalence than Western countries (possible underdiagnosis)
• Rural prevalence may be higher than urban (less diagnosis)
• Significant variation by region (South India better studied)
• Strong family-based care reducing institutional recognition

Projections

| Year | Projected Cases | Notes |
|------|-----------------|-------|
| 2025 | 8-10 million | Baseline |
| 2030 | 15 million | +75% |
| 2040 | 25 million | +200% |
| 2050 | 40 million | +400% |

Critical Note: India will have the second-highest dementia burden globally after China by 2040.

Regional Distribution

India Neurodegeneration Epidemiology

Overview

India presents a unique epidemiological challenge:

• World's most populous nation (1.4+ billion)
• Rapid demographic transition: aging population growing rapidly
• Significant regional variation in demographics and healthcare access
• Historically underrecognized neurodegenerative diseases
• Emerging research infrastructure but limited data

Alzheimer's Disease

Prevalence (2024-2025)

| Age Group | Prevalence Rate | Estimated Number |
|-----------|-----------------|------------------|
| 60-64 years | ~2-3% | ~3-4 million |
| 65-69 years | ~3-4% | ~4-5 million |
| 70-74 years | ~6-8% | ~5-6 million |
| 75-79 years | ~10-12% | ~4-5 million |
| 80+ years | ~15-20% | ~3-4 million |
| Total (60+) | ~5-7% | ~8-10 million |
| Total (all ages) | ~0.6-0.8% | ~8-10 million |

Key Characteristics:

• Lower reported prevalence than Western countries (possible underdiagnosis)
• Rural prevalence may be higher than urban (less diagnosis)
• Significant variation by region (South India better studied)
• Strong family-based care reducing institutional recognition

Projections

| Year | Projected Cases | Notes |
|------|-----------------|-------|
| 2025 | 8-10 million | Baseline |
| 2030 | 15 million | +75% |
| 2040 | 25 million | +200% |
| 2050 | 40 million | +400% |

Critical Note: India will have the second-highest dementia burden globally after China by 2040.

Regional Distribution

• South India (Karnataka, Tamil Nadu, Kerala): Most data available; higher reported prevalence
• North India (Delhi, Punjab, UP): Limited studies; likely underreported
• West India (Maharashtra, Gujarat): Moderate data
• Rural areas: Higher age-standardized rates; less healthcare access

Economic Burden

| Category | Annual Amount (INR) | USD Equivalent |
|----------|---------------------|----------------|
| Direct costs | ~₹500 billion | ~$6 billion |
| Informal caregiving | ~₹1 trillion | ~$12 billion |
| Lost productivity | ~₹300 billion | ~$3.5 billion |
| Total | ~₹1.8 trillion | ~$22 billion |
| Per-patient cost | ~₹200,000 | ~$2,400 |

Parkinson's Disease

Prevalence (2025)

| Age Group | Prevalence Rate | Estimated Number |
|-----------|-----------------|------------------|
| 50-59 years | ~0.2-0.4% | ~1-2 million |
| 60-69 years | ~0.5-0.8% | ~2-3 million |
| 70-79 years | ~1-1.5% | ~1-2 million |
| 80+ years | ~1.5-2% | ~0.5-1 million |
| Total (50+) | ~0.8-1% | ~5-7 million |

Notes:

• Lower reported than Western estimates (significant underdiagnosis)
• Possible genetic factors (LRRK2 less common, different profile)
• Rural populations significantly underdiagnosed
• Strong traditional medicine systems affect care-seeking

Projections

| Year | Projected Cases |
|------|-----------------|
| 2025 | 5-7 million |
| 2030 | 8-10 million |
| 2040 | 15-18 million |
| 2050 | 25-30 million |

Regional Distribution

• Urban areas (Mumbai, Delhi, Chennai): Better documentation
• Rural areas: Significant underreporting
• Southern states: More research and awareness

Economic Burden

| Category | Annual Amount (INR) | USD Equivalent |
|----------|---------------------|----------------|
| Direct medical | ~₹150 billion | ~$1.8 billion |
| Caregiving | ~₹200 billion | ~$2.4 billion |
| Lost productivity | ~₹100 billion | ~$1.2 billion |
| Total | ~₹450 billion | ~$5.4 billion |

Amyotrophic Lateral Sclerosis (ALS)

Prevalence (2025)

| Metric | Estimated Value |
|--------|------------------|
| Total cases | ~10,000-15,000 |
| Annual new cases | ~1,500-2,000 |
| Annual deaths | ~1,500-2,000 |
| Median survival | 2-4 years |

Characteristics:

• Lower incidence than Western countries
• Different genetic profile
• Environmental factors under study (pesticides, industrial)

Frontotemporal Dementia (FTD)

Prevalence (2025)

| Metric | Estimated Value |
|--------|------------------|
| Total cases | ~30,000-50,000 |
| Mean age at onset | 50-55 years |
| Underdiagnosis | Very significant |

Notes:

• Very limited data available
• Often misdiagnosed as psychiatric conditions
• Research programs emerging

Other Neurodegenerative Disorders

Parkinson's Plus Syndromes

| Disorder | Estimated Cases |
|----------|-----------------|
| MSA | ~5,000-8,000 |
| PSP | ~8,000-12,000 |
| CBS | ~3,000-5,000 |

Huntington's Disease

| Metric | Estimated Value |
|--------|------------------|
| Gene carriers | ~40,000-60,000 |
| Manifest patients | ~5,000-8,000 |

Healthcare System Challenges

Current Capacity

• Neurologists: ~3,000 total (1 per 500,000 population)
• Memory clinics: <100 nationwide (mostly in metro cities)
• Dementia care facilities: <50 specialized facilities
• Diagnostic capacity: Very limited in rural areas

Barriers to Care

Traditional Medicine Integration

• Ayurveda: Used extensively for cognitive symptoms
• Yoga: Complementary therapy for movement in PD
• Traditional practitioners: Often first point of contact
• Need for integration with modern neurology

Policy Response

• Dementia India Report: Advocacy and awareness
• National Programme for Healthcare of Elderly: Includes cognitive decline
• State-level initiatives: Some states have dementia programs
• Research funding: Increasing but still limited

Summary: India Neurodegeneration Burden

| Disease | Prevalence (2025) | Projected 2050 | Economic Cost |
|---------|-------------------|----------------|---------------|
| Alzheimer's Disease | 8-10 million | 40 million | ~$22 billion |
| Parkinson's Disease | 5-7 million | 25-30 million | ~$5.4 billion |
| ALS | 10,000-15,000 | Stable | ~$200 million |
| FTD | 30,000-50,000 | 100,000+ | ~$1 billion |

Key Challenges:

Cross-Links

• [Neurodegeneration Impact Measures](/diseases/neurodegeneration-impact-measures)
• [All India Institute of Medical Sciences](/institutions/aiims)
• [Epidemiology of Neurodegenerative Diseases](/diseases/epidemiology-neurodegenerative-diseases)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

References